REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan

doi:10.1016/j.jiac.2022.03.029

Observational Study

. 2022 Jul;28(7):943-947.

doi: 10.1016/j.jiac.2022.03.029. Epub 2022 Apr 7.

REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan

Ayana Sakurai¹, Shoko Marshall², Tomoko Ogasawara¹, Toshie Ogasawara¹, Yoshikazu Aoka³, Hiroshi Sakura¹, Yasuko Uchigata⁴, Tetsuya Ogawa¹

Affiliations

¹ Department of Medicine, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan.
² Department of Medicine, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan. Electronic address: marshall.shoko@twmu.ac.jp.
³ Department of General Medicine, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan.
⁴ Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan.

PMID: 35414436
PMCID: PMC8986486
DOI: 10.1016/j.jiac.2022.03.029

Observational Study

REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan

Ayana Sakurai et al. J Infect Chemother. 2022 Jul.

. 2022 Jul;28(7):943-947.

doi: 10.1016/j.jiac.2022.03.029. Epub 2022 Apr 7.

Authors

Ayana Sakurai¹, Shoko Marshall², Tomoko Ogasawara¹, Toshie Ogasawara¹, Yoshikazu Aoka³, Hiroshi Sakura¹, Yasuko Uchigata⁴, Tetsuya Ogawa¹

Affiliations

¹ Department of Medicine, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan.
² Department of Medicine, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan. Electronic address: marshall.shoko@twmu.ac.jp.
³ Department of General Medicine, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan.
⁴ Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo, 116-8567, Japan.

PMID: 35414436
PMCID: PMC8986486
DOI: 10.1016/j.jiac.2022.03.029

Abstract

Introduction: A new treatment for coronavirus disease (COVID-19), REGN-COV2, a cocktail consisting of two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been approved for patients at a risk of developing more severe disease.

Methods: We retrospectively reviewed patients recently diagnosed with COVID-19 with risk factors for severe infection, who were treated with the REGN-COV2 antibody cocktail between July and September 2021. The REGN-COV2 antibody cocktail was administered to patients within 7 days of disease onset, with an oxygen saturation of >93%, and with at least one comorbidity. We investigated the percentage of patients with COVID-19-related hospitalization or death, the duration of symptoms after treatment, and the adverse effects of treatment.

Results: A total of 108 patients were reviewed. Of them, 64% were aged ≥50 years, 31% had obesity, 36% had hypertension, and 18% had diabetes. In addition, 49% had multiple risk factors for severe COVID-19. Overall, 12 patients (11%) needed COVID-19-related hospitalization. No adverse effects of treatment were observed.

Conclusions: This study shows that treatment with the REGN-COV2 antibody cocktail is safe and beneficial in patients at a risk of developing severe COVID-19.

Keywords: Casirivimab; Imdevimab; Neutralizing monoclonal antibodies; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

None.

Cited by

Biologics in COVID-19 So Far: Systematic Review.
Arias M, Oliveros H, Lechtig S, Bustos RH. Arias M, et al. Pharmaceuticals (Basel). 2022 Jun 23;15(7):783. doi: 10.3390/ph15070783. Pharmaceuticals (Basel). 2022. PMID: 35890081 Free PMC article. Review.

References

1. Gandhi R.T., Lynch J.B., Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383:1757–1766. - PubMed
1. Matsunaga N., Hayakawa K., Terada M., Toyoda A., Suzuki K., Endo M., et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY Japan. Clin Infect Dis. 2020;73(11):e3677–e3689. - PMC - PubMed
1. Zheng Z., Peng F., Xu B., Zhao J., Liu H., Peng J., et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. - PMC - PubMed
1. Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med. 2020;167:105941. - PMC - PubMed
1. Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of hospitalized adults with COVID-19 in an Integrated Health care system in California. JAMA. 2020;323(21):2195–2198. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Gandhi R.T., Lynch J.B., Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383:1757–1766. - PubMed

[2] Gandhi R.T., Lynch J.B., Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383:1757–1766. - PubMed

[3] Matsunaga N., Hayakawa K., Terada M., Toyoda A., Suzuki K., Endo M., et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY Japan. Clin Infect Dis. 2020;73(11):e3677–e3689. - PMC - PubMed

[4] Matsunaga N., Hayakawa K., Terada M., Toyoda A., Suzuki K., Endo M., et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY Japan. Clin Infect Dis. 2020;73(11):e3677–e3689. - PMC - PubMed

[5] Zheng Z., Peng F., Xu B., Zhao J., Liu H., Peng J., et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. - PMC - PubMed

[6] Zheng Z., Peng F., Xu B., Zhao J., Liu H., Peng J., et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. - PMC - PubMed

[7] Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med. 2020;167:105941. - PMC - PubMed

[8] Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med. 2020;167:105941. - PMC - PubMed

[9] Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of hospitalized adults with COVID-19 in an Integrated Health care system in California. JAMA. 2020;323(21):2195–2198. - PMC - PubMed

[10] Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of hospitalized adults with COVID-19 in an Integrated Health care system in California. JAMA. 2020;323(21):2195–2198. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan

Affiliations

REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous